Reference
Nee R, et al. Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology : 28 Oct 2013. Available from: URL: http://dx.doi.org/10.5414/CN108100
Rights and permissions
About this article
Cite this article
Aspirin prophylaxis dominates for AVG patency in haemodialysis. PharmacoEcon Outcomes News 691, 5 (2013). https://doi.org/10.1007/s40274-013-0857-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0857-9